NASDAQ:ABAX - Abaxis Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$83.00
+0 (0.00%)
Get New Abaxis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABAX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Abaxis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $83.00.

This chart shows the closing price for ABAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Abaxis. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/31/2018SidotiReiterated RatingNeutralLow
5/16/2018Credit Suisse GroupUpgradeUnderperform ➝ NeutralLow
5/16/2018SidotiDowngradeBuy ➝ NeutralHigh
4/27/2018Stifel NicolausBoost Price TargetHold ➝ Hold$57.00 ➝ $62.00High
2/8/2018Bank of AmericaBoost Price TargetUnderperform ➝ Sell$46.00 ➝ $48.00Medium
1/26/2018Stifel NicolausBoost Price TargetHold ➝ Hold$48.00 ➝ $57.00High
1/9/2018UBS GroupUpgradeUnderperform ➝ Market PerformMedium
1/9/2018Raymond JamesUpgradeUnderperform ➝ Market PerformMedium
1/5/2018Northcoast ResearchUpgradeNeutral ➝ BuyHigh
12/1/2017AegisReiterated RatingHoldHigh
10/25/2017Bank of AmericaLower Price TargetUnderperform$42.00 ➝ $39.00N/A
8/23/2017Bank of AmericaReiterated RatingUnderperform ➝ Underperform$42.00High
7/14/2017Stifel NicolausReiterated RatingHold$48.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/6/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/5/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/4/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/5/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/4/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Abaxis logo
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.
Read More

Today's Range

Now: $83.00
Low: $83.00
High: $83.00

50 Day Range

MA: N/A

52 Week Range

Now: $83.00
Low: $43.66
High: $83.98

Volume

N/A

Average Volume

167,754 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Abaxis?

The following Wall Street analysts have issued stock ratings on Abaxis in the last year:
View the latest analyst ratings for ABAX.

What is the current price target for Abaxis?

0 Wall Street analysts have set twelve-month price targets for Abaxis in the last year.
View the latest price targets for ABAX.

What is the current consensus analyst rating for Abaxis?

Abaxis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ABAX.

How do I contact Abaxis' investor relations team?

Abaxis' physical mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company's listed phone number is 510-675-6500 and its investor relations email address is [email protected] The official website for Abaxis is www.abaxis.com. Learn More about contacing Abaxis investor relations.